Bone marrow transplantation has become an accepted modality in the treatment of acute leukemia. With this therapy, it is possible to obtain long-term disease-free survival. However, leukemia recurs occasionally. In most cases, leukemic relapse is of recipient origin. There have been several reports, though, of leukemia developing in donor cells. These cases have been limited to instances in which there is an easily identifiable chromosome difference or abnormality, usually a sex chromosome. In this paper we describe the use of restriction fragmentlength polymorphism analysis to determine the origin of recurrent leukemia cells in which no identifying chromosome was present. We found that the leukemia had recurred in recipient cells. We also were able to demonstrate the presence of normal hemopoietic cells of donor origin.
Introduction
Bone marrow transplantation has become an accepted part of the treatment of acute leukemia (1) . Although there are many disease-free long-term survivors, leukemia recurs occasionally. In most cases, recurrent leukemic cells are of recipient origin. However, there have been reports of leukemia or lymphoma developing in donors' cells (2) (3) (4) (5) (6) (7) (8) (9) . In general, these reports have been limited to transplants in which there has been a sex mismatch, and therefore an easily identifiable chromosome difference.
A method that would permit the study of the origin of hemopoietic cells from most, if not all, patients undergoing bone marrow transplantation would be desirable. This requires a more general technique than chromosome analysis. The method of restriction fragment length polymorphisms (RFLP) has this characteristic. Shubach et al. (8) (10) . In this paper, we describe the use of RFLP to determine the origin of leukemic blasts and normal cells in a patient after transplantation.
Methods
The patient was a 20-yr-old male with acute myeloblastic leukemia. At the time of bone marrow transplantation, he was in a second complete remission. The donor was the patient's younger brother. The donor's hematological values were normal at the time of transplantation. The patient was treated with 100 mg/m2 Ara-C for 5 d by continuous infusion followed by 60 mg/kg cyclophosphamide on two consecutive days. 2 d after cyclophosphamide, the patient received 500 rad total body irradiation followed immediately by infusion of donor bone marrow cells. The posttransplantation period was uneventful and on the 14th day the granulocyte count was >103/mm3. 2 mo after transplantation, the patient was discharged with normal hematological values. He was well for the next 6 mo, when a routine hematology examination revealed the presence of blasts in the peripheral blood. When blood was obtained for the studies described in this paper, the leukocyte count was 14,000/mm3, with 70% blasts, 10% granulocytes, and 20% lymphocytes. Attempts at inducing remission were unsuccessful and the patient died -2 mo after relapse.
Sources of DNA. DNA was obtained from the peripheral blood cells of the donor and the recipient. Mononuclear cells were separated by Ficoll-Hypaque centrifugation (I 1). A fraction of cells enriched for granulocytes was prepared by lysing the erythrocytes in the pellet. Populations of cells enriched and depleted for T lymphocytes were obtained by E rosette depletion of the mononuclear cell fraction (12) . The purity of the fractions was assessed by morphology of Wright stained cells.
Skin fibroblast cells were recovered from a fresh skin biopsy. Preparation of DNA. Cells were washed in phosphate-buffered saline and then resuspended in 10 mM Tris, 100 mM NaCl, I mM EDTA, pH 7.4. The cell suspension was added to an equal volume of 10 mM Tris, 100 mM NaCI, I mM EDTA, pH 7.4, containing 400 ,gg/ml of proteinase K and 1% sodium dodecyl sulfate. This suspension was incubated at 37°C overnight. The suspension was then extracted once with phenol chloroform isoamyl alcohol 25:24:1 and twice with chloroform isoamyl alcohol 24:1. The DNA was precipitated with isopropyl alcohol and resuspended in 10 mM Tris, 1 Probe. The probe used in this study was pAW 101 (D14SI) (14) . The clone was kindly provided by Dr. Ray White. The plasmid DNA was made radioactive by nick translation with 32P-alpha deoxycytidine triphosphate (15) .
Cytogenetics. Metaphase spreads were prepared from bone marrow cells at the time of initial presentation and at the time of leukemic relapse after transplantation. Metaphase spreads from phytohemaglutinin-stimulated peripheral blood cells of the donor were also analyzed.
Results
The results of this study are depicted in Fig. 1 The purity of the fraction was assessed by light microscopy of Wright stained cells. The blast-cell population consisted of >99% blasts. However, the granulocyte fraction and E rosette positive fraction contained -15% blast cells. Chromosome analysis revealed that there were no cytogenetic polymorphisms between donor and recipient cells. Also, no karyotypic abnormalities were seen in the samples obtained at presentation or following relapse after bone marrow transplantation. Thus, using cytogenetics, it was not possible to differentiate donor from recipient cells, nor was it possible to determine whether the leukemic cells at relapse were members of the original leukemic clone.
Discussion
In this case, we used the analysis of a RFLP in the DNA of the donor and recipient to identify the origin of the leukemic blast cells and the coexisting normal cells in a patient after bone marrow transplantation. The leukemic cells in this case were found to be of recipient origin. Note In the present case a polymorphic marker, recognized by pAW 101, on chromosome 14 was used (17) . pAW 101 is highly polymorphic in the population and as such is very useful. However, as there is a 25% chance that two siblings will inherit the same pair of chromosome 14s, the maximum utility of any single highly polymorphic probe is -75% of cases. In theory, by using clones that recognize polymorphisms on other chromosomes (18) , except for possibly chromosome 6, which carries the HLA genes (18) , it should be possible to identify the origin of nucleated blood cells after bone marrow transplantation in all cases except where the donor and recipient are identical twins. 
